Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $1.63, $0.11 better than the analyst estimate of $1.52. Revenue for the quarter came in at $12.2 billion versus the consensus estimate of $11.8 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2025 EPS of $6.40-$6.60, versus the consensus of $6.36. Bristol-Myers Squibb sees FY2025 revenue of $47.5-48 billion, versus the consensus of $47.34 billion.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.